Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
1(33.3%)
N/A
1(33.3%)
Phase 2
1(33.3%)
3Total
Phase 1(1)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06611930Phase 2Terminated

CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes

Role: collaborator

NCT05409924Phase 1Completed

First-in-human Single and Multiple Dose Trial of ATR-258

Role: collaborator

NCT03182829Completed

In Vitro Diagnostic Test for DOAC in Urine

Role: collaborator

NCT01549015Not ApplicableCompleted

Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function

Role: collaborator

All 4 trials loaded